Earnings summaries and quarterly performance for FEMASYS.
Executive leadership at FEMASYS.
Board of directors at FEMASYS.
Research analysts covering FEMASYS.
Recent press releases and 8-K filings for FEMY.
Femasys Expands European Commercial Footprint with Swiss Partnership
FEMY
Product Launch
New Projects/Investments
- Femasys Inc. announced a strategic distribution partnership with OR Consulting to support the commercial launch of its product portfolio in Switzerland.
- The agreement includes FemBloc Permanent Birth Control, FemaSeed Intratubal Insemination, and additional Femasys fertility and women’s diagnostic health products.
- This partnership represents a continuation of Femasys’ European expansion strategy, following recent market entry in Spain and an ongoing launch in France.
- FemBloc received full regulatory approval in Europe in June 2025, the UK in August 2025, and New Zealand in September 2025.
- FemaSeed is described as a groundbreaking first-step infertility treatment, demonstrating to be over twice as effective as traditional IUI with a comparable safety profile.
4 days ago
Femasys Granted Nasdaq Extension for Minimum Bid Price Compliance
FEMY
Delisting/Listing Issues
- Femasys Inc. received an additional 180-calendar day extension from Nasdaq to regain compliance with the US$1.00 minimum closing bid price requirement.
- The new deadline for Femasys to achieve compliance is July 13, 2026.
- This extension has no immediate effect on the continued listing status of the Company's common stock on The Nasdaq Capital Market LLC.
- Femasys plans to cure the deficiency, if necessary, by effecting a reverse stock split.
Jan 14, 2026, 2:00 PM
Femasys Announces Partnership with Refuah Health Center
FEMY
New Projects/Investments
Product Launch
- Femasys Inc. has partnered with Refuah Health Center to offer FemaSeed as a first step in infertility treatment.
- This partnership is expected to strengthen Femasys’ commercial footprint in community-based fertility care by expanding patient access and supporting increased utilization of FemaSeed.
- FemaSeed is a next-generation artificial insemination solution that achieved over double the pregnancy rates of IUI in cases of low male sperm count during its pivotal clinical trial.
- FemaSeed is authorized for use in the U.S., Europe, UK, Canada, and Israel.
Jan 13, 2026, 2:00 PM
Femasys Secures FDA Clearance for Next-Generation FemVue Diagnostic Device
FEMY
Product Launch
New Projects/Investments
- Femasys Inc. announced on December 18, 2025, that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its FemVue Controlled device.
- The FemVue Controlled device is an innovative diagnostic solution designed for controlled contrast delivery to evaluate fallopian tube status.
- This next-generation device integrates the company's original FemVue and FemChec technologies into a single FDA-cleared product, enabling multiple clinical uses and streamlining manufacturing and practice workflows.
Dec 18, 2025, 2:27 PM
Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device
FEMY
Product Launch
New Projects/Investments
- Femasys Inc. (NASDAQ: FEMY) announced on December 18, 2025, that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its FemVue Controlled device.
- The FemVue Controlled device is an innovative diagnostic solution designed for controlled contrast delivery to evaluate fallopian tube status.
- This next-generation device integrates features of the company's original FemVue and FemChec technologies into a single product, aiming to streamline manufacturing and practice workflows and enable multiple clinical uses.
Dec 18, 2025, 2:15 PM
Femasys Inc. Announces Third Quarter 2025 Financial Results and Key Milestones
FEMY
Earnings
Product Launch
Debt Issuance
- Femasys Inc. reported a 31.4% increase in sales to $729,394 for the third quarter of 2025, compared to $554,908 for the same period in 2024, primarily due to sales of FemBloc.
- The company's net loss for Q3 2025 was $4,194,821, or ($0.10) per basic and diluted share, an improvement from a net loss of $5,408,860, or ($0.24) per share, in Q3 2024.
- Femasys announced a $12 million financing through secured convertible notes and accompanying warrants, which strengthens its balance sheet and is expected to fund operations into September 2026.
- Key corporate highlights include FDA IDE approval to advance the final FemBloc® pivotal trial and regulatory approvals for FemBloc in the U.K. and New Zealand.
Nov 14, 2025, 9:09 PM
Femasys Announces Second European Partner Order for FemBloc
FEMY
Product Launch
New Projects/Investments
- Femasys Inc. secured a significant initial order valued at approximately $500,000 USD for the commercial launch of its FemBloc Permanent Birth Control in France and the Benelux region.
- This order, made through a partnership with Kebomed, marks the second partner order for FemBloc in Europe, indicating continued expansion into key European markets.
- FemBloc is a breakthrough non-surgical permanent contraceptive solution that received full regulatory approval in Europe in June 2025, the UK in August 2025, and New Zealand in September 2025.
Nov 10, 2025, 2:22 PM
Femasys Inc. Details Equity Capitalization and Securities Terms
FEMY
Debt Issuance
Convertible Preferred Issuance
- As of November 7, 2025, Femasys Inc. has 200,000,000 authorized shares of Common Stock, with 52,071,103 shares issued and outstanding and 41,656,916 shares reserved for issuance from outstanding Convertible Securities.
- The company plans to use proceeds from the sale of securities for the satisfaction of the November 2023 Notes and for working capital or other general corporate purposes.
- An "Expiration Trigger Event" for warrants will occur if the company reports two consecutive quarters of $3,250,000.00 in sales.
- The Exercise Price for certain securities will be readjusted based on changes in the number of deliverable shares, with no adjustment for exempted issuances unless aggregate net proceeds from at-the-market offerings or equity lines of credit exceed $10,000,000 in any calendar year.
Nov 7, 2025, 10:08 PM
Femasys Secures FDA Approval for FemBloc Trial and $12 Million Financing
FEMY
New Projects/Investments
Debt Issuance
Convertible Preferred Issuance
- Femasys Inc. received FDA Investigational Device Exemption (IDE) approval on November 3, 2025, to continue enrollment in the final phase (Part B) of the FINALE pivotal trial for FemBloc, a non-surgical permanent birth control, marking a critical step towards potential U.S. Pre-Market Approval (PMA).
- The company secured $12 million in senior secured convertible notes from investors, with the potential to reach $58 million if all accompanying warrants are exercised for cash.
- These notes bear an interest rate of 8.5% per annum and have a 10-year maturity, with proceeds intended to refinance existing debt and advance commercialization of Femasys' fertility and permanent birth control portfolio.
Nov 3, 2025, 2:19 PM
Femasys Initiates Post-Market Surveillance Study for FemBloc in Europe
FEMY
Product Launch
New Projects/Investments
- Femasys Inc. announced the commencement of a post-market surveillance (PMS) clinical study for its CE-marked FemBloc Permanent Birth Control in Europe.
- This study is a key component of the company's European commercialization strategy, aiming to generate real-world data to support broader physician adoption and reimbursement, while ensuring compliance with EU Medical Device Regulation (MDR).
- FemBloc, a first-of-its-kind non-surgical solution for permanent birth control, received full regulatory approval in Europe in June 2025, the UK in August 2025, and New Zealand in September 2025.
Oct 22, 2025, 1:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more